TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05109455

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MANOSAR®
Description: MANOSAR® is an authorized food supplement that contains D-mannose, Proanthocyanidins, Ursolic Acis, vitamin complexes and ions, and protects against urinary tract infections.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Proanthocyanidins
Description: The comparator are Proanthocyanidins of continuous-release, which are isolated from cranberry, and prevents the adhesion of uropathogenic bacteria such a E.coli to the wall of the urothelium.
Study: NCT03310333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propess® (dinoprostone)
Description: The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.~If the cervix is unfavourable (cervical Bishop's score \<6), the information of the study is given to the patient and the consent collected.~An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cook cervical pipening balloon
Description: • In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
Study: NCT03254576

Intervention type: OTHER
Intervention: Functional MRI

Intervention type: OTHER
Intervention: Functional MRI
Study: NCT05885178

Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.

Intervention type: PROCEDURE
Intervention: Endovascular Therapy
Description: Endovascular therapy, as an adjunct to standard stroke therapy, may be beneficial for a very select population of patients who present with an acute ischemic stroke and have a proven large, proximal occlusion on imaging.~Endovascular therapy includes any one or more of the following:~Intra-arterial thrombolytic therapy, aspiration, stent retrieval, or a combination of multiple mechanical devices.
Study: NCT03406741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychometric evaluation
Description: Wechsler type composite scales (WISC)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological evaluation
Description: Evaluation of child behavior by the Goodman questionnaire: Strengths and Difficulties Questionnaire
Study: NCT02789813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Once oral administration of 500mg before exposure therapy.
Study: NCT03167281

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: early tPA and DNase
Description: Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
Study: NCT03234283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRRIS InfraRed - Red Intubation System
Description: IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
Study: NCT03373903

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT02789813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid
Description: Once oral administration of 500mg before exposure therapy.
Study: NCT03373903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: oral
Study: NCT02789813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once oral administration of 500mg before exposure therapy.
Study: NCT03373903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235 plus everolimus (RAD001)
Description: Oral
Study: NCT02642224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Work Case Management
Description: The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
Study: NCT03920644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine Transdermal Patch [Transderm Scop]
Description: Current Motion Sickness treatment, 1 patch behind the ear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: IND, up to 6 administration of intranasal gel.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo Patch, 1 patch behind the ear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Placebo Patch, 1 patch behind the ear.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel,up to 6 administration of intranasal gel.
Study: NCT02789813

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once oral administration of 500mg before exposure therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fear reactivation
Description: Fear reactivation before exposure therapy.
Study: NCT03920644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Gel
Description: Placebo Gel,up to 6 administration of intranasal gel.
Study: NCT02789813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fear reactivation
Description: Fear reactivation before exposure therapy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: No fear reactivation
Description: No fear reactivation before exposure therapy.
Study: NCT02292914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Description: Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Study: NCT02292914

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Surgery
Description: Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
Study: NCT03560518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration)
Study: NCT01128621

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1292263
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1292263
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1292263 matching placebo
Description: Tablet
Study: NCT02789813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No fear reactivation
Description: No fear reactivation before exposure therapy.
Study: NCT02397473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galcanezumab
Description: Administered SC
Study: NCT01128621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Tablet
Study: NCT01875198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Antegrade Modular Pancreatectomy with Splenectomy
Study: NCT02397473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01875198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Antegrade Modular Pancreatectomy without splenectomy
Description: distal pancreatectomy without pancreatectomy
Study: NCT02852187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGNUS MOBIS PEEK Cage
Description: Lumbar Interbody Fusion
Study: NCT02332707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir
Description: Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.
Study: NCT02852187

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIGNUS MOBIS II ST Cage
Description: Lumbar Interbody Fusion
Study: NCT05346822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: integrated rehabilitation (the collaborative patient education)
Description: Pre-operative education and rehabilitation. During hospitalization: group rehabilitation education program. Discharge: post-operative care navigation for total knee arthroplasty
Study: NCT01024309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-Posterior surgical approach for total hip arthroplasty
Description: Mini-Posterior surgical approach for total hip arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Anterior surgical approach for total hip arthroplasty
Description: Direct Anterior surgical approach for total hip arthroplasty
Study: NCT02908100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0853
Description: Participants received GDC-0853 at dosages of 150 or 200mg as per the dosing schedules described above.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo to GDC-0853 at dosages of 150 and 200mg as per the dosing schedules described above.
Study: NCT03014999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High frequency rTMS (repetitive Transcranial Magnetic Stimulation)
Description: Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 10Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)
Description: Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS (repetitive Transcranial Magnetic Stimulation)
Description: The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
Study: NCT03271645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Depression
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Anxiety
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Space from Stress
Description: The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face counselling
Description: Face-to-face counselling
Study: NCT00796445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK 2132231A
Description: IM solution, a course of 13 injections administered over 27 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IM solution, a course of 13 injections administered over 27 months
Study: NCT04367051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withdrawal of Spironolactone
Description: Other recommended medications for heart failure than spironolactone will be continued for withdrawal group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of spironolactone
Description: Specific dose of spironolactone for continuation group is on each physician's discretion with acceptable range of 12.5 mg - 50 mg once or twice daily.
Study: NCT04405466

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples

Intervention type: PROCEDURE
Intervention: Throat swab
Description: Throat swab

Intervention type: PROCEDURE
Intervention: Throat swab
Description: Throat swab

Intervention type: PROCEDURE
Intervention: Throat swab
Description: Throat swab
Study: NCT02208063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daptomycin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic penicillin
Study: NCT04024800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AE37 Peptide vaccine
Description: Starting dose: AE37 vaccine 1000 micrograms split into 2 doses given as intradermal injection on day 1 of every 3 week cycle (21 day cycle) for 5 cycles.~Should ≥ grade 3 systemic toxicities (DLT) occur in \> 25% (4) of the first 13 patients (4 or more) the study therapy vaccine dose will be de-escalated to 500 micrograms (dose level -1).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on day 1 of every 3 week cycle (21 day cycle) for 2 years (35 cycles)
Study: NCT02208063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study: NCT04036292

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC-01 (varenicline) nasal spray
Description: OC-01 (varenicline) nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle) nasal spray
Description: Placebo (vehicle) nasal spray
Study: NCT00669942

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to AIN457
Study: NCT02550678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASN-002
Description: ASN-002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon-gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU is chemotherapeutic agent used to treat various cancers.
Study: NCT01474122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 3 mg
Description: Macitentan 3-mg tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 10 mg
Description: Macitentan 10-mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matching macitentan tablet, once daily
Study: NCT02522234

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627 240 μg/kg
Description: F-627 at 240 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 240 μg/kg arm. And the arm should contain 6 evaluable subjects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627 320 μg/kg
Description: F-627 at 320 μg/kg dose enrolling 6 patients with breast cancer receiving adjuvant chemotherapy. Subjects will receive a corresponding dose of F-627 by subcutaneous injection 24 hours after each cycle（21 days） of chemotherapy drug administration. Blood samples are then collected at multiple time points during follow-up visits to evaluate the pharmacokinetics, pharmacodynamics, and safety of the drug. Dose will remain unchanged throughout the treatment period. Eligible subjects will be enrolled sequentially into the 320 μg/kg arm. The arm should contain 6 evaluable subjects.
Study: NCT02914600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgotinib
Description: Tablet administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet administered orally once a day
Study: NCT04898361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFO closure
Description: Interventional closure of a patent foramen oval preceded by an electrophysiological study